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Angiotensin II inhibits growth of cultured embryonic renomedullary
interstitial cells through the AT2 receptor. The high abundance of
angiotensin II (Ang II) AT2, relative to the AT1 receptor subtype in
developing kidneys may be related to their potential as mediators of cell
growth, although little evidence exists to support this concept. Renomed-
ullary interstitial cells (RMICs) differentiate early in embryonic kidneys
and are important in subsequent nephron development. These cells have
been shown in vivo to possess AT2 binding sites, although the functional
significance of these sites remains unknown. The aim of the current
investigation was to examine the actions of Ang II on cultured embryonic
renomedullary interstitial cells (ERMICs). 125I-[Sar1, Ile8]Ang II specifi-
cally bound to AT1 and AT2 receptors on ERMICs, and their mRNAs
were detected by reverse transcription—polymerase chain reaction (RT-
PCR). Angiotensin II (1026 M) increased intracellular IP3 concentrations
at 20 seconds, and decreased intracellular cAMP concentrations after 10
minutes. Angiotensin II (1026 M) induced an increase in [3H]thymidine
incorporation, mediated through the AT1 receptor subtype. Basic fibro-
blast growth factor (bFGF; 20 ng/ml) also increased 3[H]thymidine
incorporation after 24 hours of treatment, an effect that was attenuated by
subsequent addition of Ang II (1026 M). This antiproliferative action of
Ang II was blocked by PD 123319 (1026 M), an AT2 receptor antagonist,
and was not affected by losartan (1026 M), an AT1 receptor antagonist.
These results indicate a dual role for Ang II in regulating ERMIC
mitogenesis: a growth stimulating effect mediated by the AT1 receptor
subtype, and an antiproliferative effect mediated by the AT2 receptor
subtype.
Angiotensin II (Ang II) has well demonstrated roles in the
regulation of cardiovascular hemodynamics, secretion of miner-
alocorticoids and water and electrolyte balance [1, 2]. More
recently, Ang II has been reported to have growth promoting
properties in a number of cell types [3, 4]. To date, two subtypes
of the Ang II receptor have been identified, AT1 and AT2.
However, most of the known functions of Ang II appear to be
mediated through the AT1 receptor subtype. The high abundance
of AT2 receptors in fetal tissues has lead to the hypothesis that
Ang II, acting via the AT2 receptor, is involved in aspects of
organogenesis. In vitro studies have suggested the involvement of
AT2 receptors in mediating programmed cell death (apoptosis)
[5] and cell differentiation [6, 7].
In a previous study, we reported Ang II promotion of cell
proliferation and extracellular matrix (ECM) synthesis in cultured
rat RMICs through the AT1A receptor subtype [8]. These findings
suggested that the interactions between Ang II and these cells
may be important in the progression of renal diseases as well as in
normal renal development. Studies on the development of the
renal interstitium have suggested that renomedullary interstitial
cells (RMICs) differentiate from the nephrogenic mesenchyme
early in embryogenesis, and subsequently play an important role
in nephron development [9]. At this stage these cells possess both
AT1 and AT2 receptors. In the current study, embryonic renomed-
ullary interstitial cells (ERMICs) were isolated from embryonic
rat kidneys to examine the actions of Ang II on cell proliferation
related to their potential role in renal development.
METHODS
Cell isolation and culture
Embryos were obtained from time plug mated Sprague-Dawley
rats at 15 days of gestation. The age of the embryos was
determined from the vaginal plug, the appearance of which was
designated as embryonic day 0. The kidneys were dissected and
digested with 0.1% collagenase type I (Worthington Biochemical
Co., Freehold, NJ, USA) for 30 minutes at 37°C. Digested tissue
was sieved through a 75 mm stainless steel mesh and dispersed
cells resuspended in a 1:1 mixture of culture medium RPMI 1640
and Dulbecco’s modified Eagle’s medium (DMEM), conditioned
by 3T3 Swiss albino mouse fibroblasts in the log phase of growth.
Both culture media were supplemented with 20% fetal calf serum
(FCS), 4 mM glutamine, 50,000 U/liter penicillin G and 50 mg/liter
streptomycin sulfate. In addition, culture medium RPMI 1640
also contained 25 mM N-2-hydroxyethylpiperazine-N9-2-ethane-
sulfonic acid (HEPES) and 0.22 U/ml insulin (Sigma Chemical
Co., St. Louis, MO, USA). Cultures were maintained at 37°C in a
95% O2/5% CO2 humidified incubator. Once a homogeneous cell
population was obtained, the cells were maintained in media
supplemented with 10% FCS only. Sub-confluent cells between
passages 3 to 10 were used in all subsequent experiments.
All culture media and supplements, unless otherwise stated,
were obtained from CSL Diagnostics (Parkville, VIC, Australia).
All experimental procedures were approved by the Institutional
Animal Ethics Committee according to guidelines produced by
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Cell morphology
Sub-confluent cells were fixed in 10% buffered formalin for one
hour at room temperature and stained with Oil Red O for
demonstration of intracellular neutral lipids. For transmission
electron microscopy, cells were fixed in 2.5% glutaraldehyde in 0.1
M phosphate buffer (PB, 100 mM Na2HPO4, 150 mM NaCl, pH
7.35) for one hour at room temperature, postfixed in 2% OsO4
buffered in 0.1 M PB for one hour at room temperature, dehy-
drated in graded ethanol solutions and embedded in Epon. Thin
(90 to 100 nm) sections were cut, stained with uranyl acetate and
lead citrate and examined with a Siemens Elmiskop 102 at 60 kV.
For scanning electron microscopy, cells were fixed in the same
fixative, dehydrated in graded ethanediol solutions and cellosolve,
critical point dried, sputter coated with gold and viewed in a
Phillips 515 scanning electron microscope at 20 kV. For immu-
nocytochemical localization of a-actin, cells were fixed in Bouin’s
fluid for one hour at room temperature, washed with phosphate
buffered saline (PBS) and incubated with 1 mM proteinase K
(Sigma Chemical Co.) for 30 minutes at 37°C. Cells were incu-
bated with 1:10 dilution normal goat serum for 30 minutes at
room temperature, and then with a primary antibody (monoclo-
nal, mouse-anti-goat a-actin; Sigma) at a dilution 1:600 in PBS
overnight at 4°C. Endogenous peroxidase activity was blocked
with 3% H2O2 in methanol, following which the sections were
washed and secondary goat-anti-rabbit, biotinylated antiserum
applied for one hour at room temperature. The specific immuno-
reaction was amplified using the avidin-biotin complex (Vec-
tastain ABC kit, Elite, Vector Laboratories, Burlingame, CA,
USA) at dilution 1:50 for one hour at room temperature, and the
positive immunoreactive staining was identified using 3,-39-diami-
nobenzidine tetrahydrochloride dihydrate (DAB; Aldrich Chem-
ical Co. Inc., Milwaukee, WI, USA) at a dilution 1:50 in PBS with
3% H2O2. Negative controls were incubated with 1:10 normal
goat serum in PBS instead of the primary antiserum. Positive
controls in sections of rat aorta were incubated with the primary
antiserum.
Reverse transcribed—polymerase chain reaction and Southern
blot analysis
RNA was isolated from homogenized embryonic day 15 (E15)
rat kidneys and from cultured rat ERMICs. Isolation of RNA was
carried out using a method described by Chomczynski and Sacchi
[10]. Reverse transcription (RT) reaction of 0.5 mg RNA was
performed in 100 mM KCl, 50 mM Tris-HCl (pH 8.4), 6 mM MgCl2,
10 mM dithiothreitol (DTT), 500 mM dNTPs (Progen, Darra,
QLD, Australia), 12 mg/ml random hexamers (Boehringer Mann-
heim, Castle Hill, NSW, Australia), 40 units RNasin (Progen,
Darra, QLD, Australia), and AMV reverse transcriptase (25 units;
Boehringer Mannheim, Castle Hill, NSW, Australia) at 42°C for
one hour. The RT reaction was followed by a polymerase chain
reaction (PCR). The primers used for the amplification of AT1
receptor mRNA were: sense 59 TTGGAAACAGCTTGGTGGT-
GAT 39; antisense 59 CCAGGAAAAGAAGAAGAAAAGCAC
39 corresponding to regions 131 to 152 and 736 to 759 of the rat
AT1A receptor, respectively [11], and are identical in the rat AT1B
sequence [12]. The primers used for amplification of AT1B
receptor mRNA were: antisense 59 AGCCTTCTTTAGAGCTT-
TCCAAATAAG 39; corresponding to regions 649 to 675 of the
rat AT1A receptor, [11], and has a single mismatch with the AT1B
receptor mRNA. The sense primer was: 59 TCCAGCGC-
CACGCTGT 39, corresponding to region 20 to 35 of the rat AT1B
sequence [12]. The primers used for amplification of the AT2
receptor mRNA were: sense 59 GCTGATTTATGATAACT-
GCTTTAAAC 39; antisense 59 AGGTCCAAAGAGCCAGT-
CATATCTATAAGA 39; corresponding to regions 74 to 49 and
313 to 342 of the rat AT2 receptor, respectively [13]. Polymerase
chain reaction was performed in a solution containing: 10 mM
Tris-HCl (pH 8.3), 50 mM KCl, 400 mM dNTPs, Taq Polymerase
(2.5 units; Bresatec, Adelaide, SA, Australia), 3 mM MgCl2, and
each primer at 400 nM. Denaturation, annealing and extension
were carried out at 94°C, 60°C and 72°C for one minute each for
30 to 40 cycles, followed by a final extension at 72°C for 10
minutes. The PCR products were analyzed by electrophoresis on
a 1.4% agarose gel, then transferred to Hybond N1 (Amersham,
Buckinghamshire, UK) using alkali blotting. The membrane was
hybridized with a 32P-labeled oligonucleotide probe in Rapid-Hyb
(Amersham, Buckinghamshire, UK) at 42°C for one hour, washed
four times in 0.3 M NaCl/0.03 M sodium citrate/0.1% sodium
dodecyl sulphate (SDS) pH 7.0 at 50°C, exposed and autoradio-
graphed for 10 minutes. The oligonucleotide probe used for the
Southern blot of the AT1A and the AT1B receptor PCR products
was to the region 284 to 314 of the rat AT1A receptor [11]. This
probe has one mismatch (31nt) between the two subtypes. The
oligonucleotide probe used for the Southern blot of the AT2
receptor PCR product was to the region 72 to 111 of the rat AT2
receptor mRNA [13].
Receptor binding assay
Sub-confluent cells were made quiescent with serum-free RPMI
1640 medium for 24 hours. Cells were washed twice with PB and
harvested into PB containing 10 mm leupeptin, 1 mM phenylmeth-
ylsulfonyl fluoride (PMSF) and 5 mM EDTA. Following centrifu-
gation at 3000 rpm for 10 minutes at 4°C, cells were resuspended
in PB containing 0.1% bovine serum albumin (BSA), 0.1%
bacitracin and 5 mM DTT. Following incubation of cells with 1026
M Ang II amide for non-specific binding (NSB), PB for total
binding (TB), 1026 M losartan for AT2 subtype or 10
26 M PD
123319 for AT1 subtype binding,
125I-[Sar1, Ile8]Ang II was added
at a dose of 3 3 105 cpm/sample for two hours at rt. The cells were
then thoroughly washed and bound radioactivity measured in a
Packard gamma counter.
Inositol 1,4,5-triphosphate radioimmunoassay
Sub-confluent RMICs were scraped, resuspended in HEPES
buffer (140 mM NaCl, 4.6 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10
mM glucose, 10 mM HEPES, pH 7.3) and pelleted by centrifuga-
tion. This procedure was repeated three times. After the final
pelleting, cells were resuspended in HEPES buffer and the
protein content of the samples was determined using the Lowry
assay [14]. Cells were allowed to equilibrate at 37°C for three
minutes, and either vehicle (HEPES buffer) or Ang II (10210 and
1026 M) in the presence or absence of the AT1 receptor antagonist
losartan (1026 M) or the AT2 receptor antagonist PD 123319
(1026 M), were added for 10 or 15 seconds. The cells were then
treated with ice-cold 10% perchloric acid (PCA) for 10 minutes
and samples neutralized with a 1:1 mixture of tri-n-octyl amine
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and 1,1,2-trichlorotriluoroethane as previously described [15].
Following centrifugation at 10,000 rpm for two minutes, the
supernatants were assayed for inositol 1,4,5-triphosphate (IP3)
content using a commercially available kit (Amersham, Bucking-
hamshire, UK).
cAMP radioimmunoassay
Embryonic renomedullary interstitial cells were grown to sub-
confluency and prepared for the assay in the manner described for
IP3 measurements. Cell samples were allowed to equilibrate for
three minutes at 37°C in the presence or absence of 1023 M
3-isobutyl-1-methylxanthine (IBMX), a non-selective phosphodi-
esterase inhibitor. Then either vehicle (HEPES buffer) or Ang II
(10211 and 1026 M) in the presence or absence of the AT1
receptor antagonist losartan (1026 M) or the AT2 receptor antag-
onist PD 123319 (1026 M) were added. After 1, 2 or 10 minutes,
the reaction was stopped by the addition of 10% PCA for 10
minutes at 4°C. Supernatants, obtained after centrifugation at
10,000 rpm for two minutes, were neutralized as described for the
IP3 assay. Neutralized samples were freeze-dried, resuspended in
assay buffer (50 mM sodium acetate, 1 mM theophylline, 1 mg/ml
BSA, 0.1% sodium azide, pH 5.0) and acetylated with a 1:2
mixture of acetic anhydride and triethylamine. Antibodies to
cAMP (1:3600) and 125I-[cAMP] were added to the acetylated
samples and left at 4°C for 48 hours to allow binding. Samples
were then treated with 5% IgG and 15% polyethylene glycol,
incubated for 30 minutes at 4°C, centrifuged at 4000 rpm for 30
minutes at 4°C and the radioactivity of the pellets counted in a
Packard gamma counter.
3[H]thymidine incorporation
The ERMICs were plated at a density of 7 3 103 cells/cm2 in 1:1
RPMI 1640:conditioned DMEM culture medium containing all
supplements as indicated above. After 24 hours of plating, the
cells were serum-starved for 48 hours. To examine the effect of
Ang II on ERMIC proliferation, the cells were treated with
serum-free medium (control), or Ang II (10211-1026 M) with or
without 1026 M losartan or 1026 M PD 123319 for 5 to 53 hours.
To examine the possible interactions of Ang II and bFGF with
ERMIC proliferation, the cells were pre-treated with 20 ng/ml
bFGF for 24 hours followed by the addition of 1026 M Ang II with
or without 1026 M losartan or 1026 M PD 123319 for additional 24
hours. Throughout the treatment period, the cells examined for
evidence of apoptotic figures by phase contrast microscopy.
Following treatment, a pulse dose of 1 mCi/ml [3H]thymidine
(Amersham) was applied for five hours at 37°C, after which the
cells were washed with ice-cold PBS and 5% trichloroacetic acid.
The samples were then solubilized with 0.25 M NaOH and 0.1%
SDS for 30 minutes at 37°C, and incorporated radioactivity was
measured in a Packard liquid scintillation counter.
Statistical analysis
Results are expressed as mean 6 SD (unless otherwise stated)
and analyzed using two-way analysis of variance and the multiple
comparison Tukey test. Statistical significance was assigned to
values where P , 0.05.
RESULTS
Cell morphology
A homogeneous cell population was reached at passage 3. At
this stage, these cells resembled RMICs found in vivo [9] as well
as cultured RMICs isolated from adult kidneys [8]. The cells were
stellate-shaped and projected numerous cytoplasmic processes
contacting neighboring ERMICs (Fig. 1B). They showed charac-
teristics of protein synthesizing cells, containing numerous rough
endoplasmic reticulum (RER) inclusions with dilated cisternae, a
moderate number of mitochondria and condensation of chroma-
tin in the nucleus (Fig. 1A). Characteristic lipid droplets, demon-
strated both by light and transmission electron microscopy, were
abundant (Fig. 1C). The presence of a-actin filaments was dem-
onstrated by immunocytochemistry (Fig. 1D). Abundant lipid
droplets and a-actin filaments are characteristic of both ERMICs
in vivo [9] and RMICs derived from adult kidneys [8].
Reverse transcription-polymerase chain reaction and Southern
blot analysis
A PCR product corresponding to the AT1 receptor was local-
ized to the homogenized E15 kidney preparation as well as to
cultured ERMICs (Fig. 2) [15]. We have previously demonstrated
that adult RMICs express only the AT1A subtype whereas whole
kidney expresses both AT1A and AT1B receptor mRNA [8]. We
examined whether ERMICs express AT1B receptor mRNA using
RT-PCR, but could not detect its expression even after 40 cycles
and Southern blotting, whereas it was clearly detectable in E15
kidneys. In addition, a band corresponding to the AT2 receptor
subtype was localized to E15 kidneys as well as to cultured
ERMICs.
Receptor binding assay
Following a one hour incubation, ERMICs specifically bound
125I-[Sar1, Ile8]Ang II (NSB, 0.20 6 0.04 3 107 cpm/mg protein;
TB, 1.2 6 0.2 3 107 cpm/mg protein; N 5 5; P , 0.001; Fig. 3).
Binding was partially displaced by 1026 M losartan (0.60 6 0.02 3
107 cpm/mg protein; N 5 2; P , 0.01) and by 1026 M PD 123319
(0.90 6 0.01 3 107 cpm/mg protein; N 5 2; P , 0.01), indicating
the presence of both the AT1 and AT2 receptor subtypes.
Effect of angiotensin II on intracellular IP3
Treatment of ERMICs with Ang II (1026 M) increased intra-
cellular IP3 concentrations. A marked increase was detected 20
seconds after treatment (control, 1.7 6 0.7 pmol/mg protein; Ang
II, 68.0 6 2.5 pmol/mg protein; N 5 4; P , 0.01; Fig. 4). This
effect was completely abolished in the presence of 1026 M losartan
(1.4 6 0.4 pmol/mg protein; N 5 3), but not affected in the
presence of 1026 M PD 123319 (57.0 6 2.8 pmol/mg protein; N 5
3; P , 0.01). Angiotensin II (10210 M) had no effect on IP3 at any
time point chosen.
Effect of angiotensin II on intracellular cAMP
No changes in intracellular cAMP concentrations were de-
tected following treatment of ERMICs with Ang II (1026 and
10210 M) for one or two minutes (Fig. 5A), either in the presence
or absence of IBMX (1023 M). However, in the presence of
IBMX, 10 minutes following treatment with Ang II (1026 M), a
decrease in intracellular cAMP concentration was observed (con-
trol, 2731 6 255 fmol/mg protein; Ang II, 1536 6 194 fmol/mg
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protein; N 5 4; P , 0.05), (Fig. 5). This effect was completely
abolished with 1026 M losartan (1311 6 119 fmol/mg protein; N 5
3) but not affected with 1026 M PD 123319 (2289 6 191 fmol/mg
protein; N 5 3; P , 0.05; Fig. 5B).
Effect of angiotensin II on [3H]thymidine incorporation
Treatment of ERMICs with Ang II (10210 to 1026 M) for 5 to
53 hours resulted in time- and dose-dependent increases in
[3H]thymidine incorporation. Following treatment for 29 hours
with increasing doses of Ang II, significant increases in [3H]thy-
midine incorporation were observed. The lowest dose of Ang II
effective in increasing [3H]thymidine incorporation after 29 hours
was 1029 M (control, 1735 6 110 cpm/well; Ang II, 2112 6 182
cpm/well; N 5 3; P , 0.05; Fig. 6A). Increases in [3H]thymidine
incorporation following treatment with 1026 M were first observed
after 11 hours, and increased further after a 29 hours treatment
(control, 1735 6 110 cpm/well; Ang II, 4175 6 169 cpm/well; N 5
8; P , 0.01; Fig. 6B). The response to Ang II 1026 M was
completely abolished in the presence of losartan 1026 M (1284 6
62 cpm/well), but not affected in the presence of PD 123319 1026
M (3724 6 79 cpm/well).
Basic fibroblast growth factor (bFGF; 20 ng/ml) also increased
[3H]thymidine incorporation after 29 hours of treatment (8799 6
Fig. 1. (A) A transmission electron micrograph showing an irregularly shaped embryonic renomedullary interstitial cell (ERMIC) with several
cytoplasmic processes, a nucleus (N), abundant rough endoplasmic reticulum (RER) and lipid inclusions (arrowheads) (33600). (B) A scanning
electron micrograph of ERMICs demonstrating their irregular shape and the presence of numerous cytoplasmic processes (33000). (C) A wholemount
of ERMICs stained with Oil Red O showing numerous lipid droplets (arrows) (31200). (D) a-Actin filaments (a-actin), stained using immunocyto-
chemistry, form dense condensations at peripheral cell contact points (3800).
Fig. 2. RT-PCR for AT1A (top panel), AT1B (middle panel) and AT2
(bottom panel) was performed on RNA from ERMICs (E) and E15 kidney
homogenate (K). No DNA was added for negative controls (O). Molecular
size markers are given on the left.
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966; N 5 5; P , 0.001; Fig. 7). However, in the presence of bFGF,
the addition of Ang II (1026 M) during a further 24 hours
attenuated the bFGF-induced [3H]thymidine incorporation
(3261 6 284 cpm/well). The ability of Ang II to attenuate cell
proliferation induced by bFGF was not altered by losartan (1026
M), but was abolished by PD 123319 (1026 M), indicating that this
antiproliferative action of Ang II is mediated through the AT2
receptor subtype.
During the treatment periods, morphological examination of
cells by phase contrast microscopy showed no evidence of apo-
ptosis (nuclear fragmentation or condensation; graphic not
shown).
DISCUSSION
The high abundance of AT2 binding sites in embryonic tissues,
including kidney, has suggested their potential importance in the
control of cell growth. Although recent studies have reported a
role for these receptors in mediating apoptosis [5] and cell
differentiation [6, 7], the cells displaying these properties have
been derived from either adult or tumor tissues. Thus, the
postulated role for the AT2 receptor in development still remains
unclear.
To date, the precise localization of the AT2 receptors in the
developing kidney has not been reported although high levels of
mRNA for these receptors have been detected in the interstitium
surrounding the collecting ducts [16]. Renomedullary interstitial
cells are the predominant cell type in this region and are believed
to have an important role in kidney morphogenesis [9]. Thus,
characterization of the cellular responses of embryonically de-
rived RMICs to Ang II was undertaken in the present study.
The radiolabeled binding assay and RT-PCR revealed the
presence of both AT1 and AT2 receptor subtypes and their
mRNAs in ERMICs. However, binding of 125I-[Sar1, Ile8] Ang II
to AT2 receptors was only observed in the presence of DTT, which
has been previously reported to non-selectively increase AT2 and
decrease AT1 receptor binding [17]. The likely explanation for
these effects may be that the cells possess low numbers of AT2
binding sites.
Increases in intracellular IP3 concentrations were measured 20
seconds following binding of Ang II to ERMICs. This response
had a slower onset than that observed in response to Ang II
treatment of RMICs derived from adult kidneys [8], but the
reason for this is unclear. Previous studies have indicated that
increases in IP3 and calcium concentration occur following bind-
ing of Ang II to AT1 receptors in a number of cell types [18] and
it is likely that a similar pathway is present in ERMICs. The most
recent evidence on the signal transduction pathways associated
with AT2 receptor activation indicates an association with Gai2
and Gai3 proteins in fetal tissues [19] and inhibition of mitogen-
activated protein kinase activity via Gai and protein phosphatase
2A [20].
We have demonstrated that Ang II acts as a potent mitogen to
ERMICs in a time- and dose-dependent manner. This effect was
abolished with losartan but not with PD 123319, suggesting that
Fig. 3. Binding of angiotensin II (Ang II) to embryonic renomedullary
interstitial cells (ERMICs): 125I-[Sar1, Ile8] Ang II bound to ERMICs,
with low levels of non-specific binding (NSB) also detected. Total binding
(TB) of 125I-[Sar1, Ile8] Ang II to ERMICs was partially abolished with
losartan (1026 M), the AT1 specific receptor antagonist, and partially with
PD 123319 (1026 M), the AT2 specific receptor antagonist. Values are
means 6 SD of 2 experiments in duplicate. ***P , 0.001 vs. NSB.
Fig. 4. Effect of angiotensin II (Ang II) on IP3. No changes in IP3
concentration were observed 10 seconds following treatment with Ang II.
Following treatment of embryonic renomedullary interstitial cells (ER-
MICs) with Ang II (1026 M) for 20 minutes, IP3 concentrations were
increased. This effect was abolished with losartan (1026 M), but not with
PD 123319 (1026 M). Values are means 6 SD of 4 experiments in duplicate.
***P , 0.001 vs. control at the same time point.
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the mitogenic effect of Ang II is mediated through the AT1
receptor. Although the maximal doses inducing cell proliferation
and also affecting the second messenger pathways were relatively
high (1026 M), studies measuring the interstitial concentrations of
Ang II in the kidney have shown greater concentrations of Ang II
in the interstitial compartments than in plasma [21]. Thus, the
results obtained in the current study following treatment with
1026 M Ang II may reflect the in vivo responses of ERMICs to
Ang II. The extent of [3H]thymidine incorporation induced by
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Fig. 5. Effect of angiotensin II (Ang II) on cAMP. (A) A decrease in
intracellular cAMP concentration was observed 10 minutes following
treatment with Ang II (1026 M). Ang II (10210 M) had no effect on cAMP.
*P , 0.05 vs. control at the same time point. (B) Ang II-induced decrease
in cAMP concentration was abolished with 1026 M losartan (LOS), but not
with 1026 M PD 123319 (PD). Values are means 6 SD of 3 experiments in
duplicate. *P , 0.05 vs. control.
Fig. 6. Effect of angiotensin II (Ang II) on [3H]thymidine incorporation.
(A) Ang II-induced increase in [3H]thymidine incorporation was dose
dependent. The lowest effective dose was 1029 M after 29 hours of
treatment. (B) Treatment of embryonic renomedullary interstitial cells
(ERMICs) with Ang II (1026 M) resulted in an increase in [3H]thymidine
incorporation observed after nine hours and increased after 29 hours. This
effect was abolished in the presence of losartan (1026 M), but not altered
in the presence of PD 123319 (1026 M). Values are means 6 SD of 8
experiments in duplicate. **P , 0.01; ***P , 0.001 vs. control at same
time point.
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Ang II was reduced when compared with that observed in adult
RMICs [8]. Considering the embryonic origin of the cells used in
the current study, a higher rate of proliferation might have been
expected. The contrary finding suggests either that cultured
ERMICs posses a lower number of AT1 binding sites than adult
RMICs or that there exist several growth regulating mechanisms
in addition to that activated by Ang II.
In addition to Ang II, other vasoactive peptides and/or growth
factors also induce mitogenesis in ERMICs (unpublished obser-
vations). Among these factors, bFGF was the most potent in
inducing cell proliferation. In the present study, ERMICs were
treated for 29 hours with bFGF and then with Ang II. After the
addition of Ang II, the bFGF-induced increase in [3H]thymidine
incorporation was attenuated. This antiproliferative effect of Ang
II was not apparent following addition of PD 123319, but was
maintained following addition of losartan, suggesting that it was
mediated through the AT2 receptor. The ability of Ang II to
inhibit growth induced by bFGF has recently also been reported
in coronary endothelial cells [6], where a similar action was also
mediated by the AT2 receptor.
Results obtained in the current study suggest that Ang II,
engaging both AT1 and AT2 receptors, has a dual role in
regulating proliferation of ERMICs. Under conditions when only
Ang II is present in the culture medium, it acts as a growth
promoting factor via the AT1 receptor. However, if proliferation
had already been promoted by a factor such as bFGF, Ang II
activates the AT2-mediated antiproliferative mechanism. These
findings suggest that the antiproliferative action of the AT2
receptor is not an inherent property, but is only recalled in states
of active proliferation.
High levels of AT2 receptor expression are associated with
other developing tissues including adult adrenal gland and ovary
[22, 23]. In addition, increased expression of AT2 receptors has
been associated with left ventricular hypertrophy and vascular
neointimal proliferation [24, 25]. Thus, the sites of AT2 expression
correspond to sites of active growth and differentiation. This is
consistent with the findings of the current study where the
function of AT2 receptors was only apparent under conditions of
stimulated growth.
During kidney development, ERMICs differentiate from the
nephrogenic mesenchyme to subsequently play a role in nephro-
genesis and basement membrane formation [9]. The ability of Ang
II to regulate ERMIC proliferation demonstrates an important
role for Ang II in kidney morphogenesis. Chronic blockade of the
renin-angiotensin system during kidney development results in
morphological abnormalities accompanied by impaired renal
function [26, 27]. Although such studies have been performed in
postnatal animals in which the majority of the receptors are of the
AT1 subtype, these observations highlight the importance of Ang
II in regulating developmental processes in the kidney. Blockade
of AT2 receptors from an early stage in embryonic development
may provide insight into the physiological relevance of this
receptor in renal morphogenesis.
This study has demonstrated the presence of biologically active
AT1 and AT2 receptors on ERMICs. Both receptors play a role in
regulating ERMIC proliferation with opposing effects. Most
importantly, this study demonstrates a physiological role for AT2
receptors on cells that are actively involved in regulating kidney
morphogenesis. Thus, through both its receptor subtypes Ang II
appears to play an important role in regulating kidney develop-
ment.
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APPENDIX
Abbreviations used in this article are: Ang II, angiotensin II; RMICs,
renomedullary interstitial cells; ERMICs, embryonic renomedullary inter-
stitial cells; AT, angiotensin receptors; RT-PCR, reverse transcription—
polymerase chain reaction; bFGF, basic fibroblast growth factor; ECM,
extracellular matrix; DMEM, Dulbecco’s modified Eagle’s medium; FCS,
fetal calf serum; HEPES, N-2-hydroxyethlpiperazine-N9-2-ethanesulfonic
acid; PB, phosphate buffer; PBS, phosphate buffered saline; DAB,
3,–39-diaminobenzidine tetrahydrochloride dihydrate; DTT, dithiothrei-
tol; SDS, sodium dodecyl sulphate; PMSF, phenylmethylsulfonyl fluoride;
BSA, bovine serum albumin; NSB, nonspecific binding; TB, total binding;
PCA, perchloric acid; IBMX, 3-isobutyl-1-methylxanthine; E15, embry-
onic day 15.
Fig. 7. Effect of basic fibroblast growth factor (bFGF) on [3H]thymidine
incorporation. bFGF (20 ng/ml) induced an increase in [3H]thymidine
incorporation 29 hours following treatment. Subsequent addition of Ang
II (1026 M) for another 24 hours attenuated the bFGF-induced 3[H]thy-
midine incorporation. This effect was abolished with PD 123319 (1026 M),
and not affected with losartan (1026 M). Values are means 6 SD of 6
experiments in duplicate. **P , 0.01; ***P , 0.001 vs. control.
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